Combined HCC-MFCCC

University of Milan100 enrolled

Overview

Combined hepatocellular and mass-forming cholangiocarcinoma (cHCC-MFCCC) is a rare tumor. The aim of this study was the analysis of the outcome comparing such tumor with classic hepatocellular carcinoma (HCC) and mass-forming cholangiocarcinoma (MFCCC).

The institutional prospectively maintained database was queried, and 20 patients with cHCC-MFCCC were identified. A 2:1 match was performed with 40 patients operated in the same period for HCC, and with 40 operated for MFCCC. Only T1 or T2 patients N0 M0 were considered. Primary endpoint was the overall survival (OS) and disease-free survival (DFS).

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Liver Carcinoma Hepatocellular Carcinoma Cholangiocarcinoma Surgery

Interventions

HepatectomyPROCEDURE

Removal of a part of the liver

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * positive histology for cHCC-MFCCC, HCC, and MFCCC * complete clinical, surgical, pathological and follow-up data. Exclusion Criteria: * patients preoperatively treated with chemotherapy, radiofrequency ablation or trans-arterial therapies were excluded. * patients operated for recurrent disease and/or with non-radical surgery * patients with missing data were also excluded

Outcomes

Primary Outcomes

Survival analysis

Analysis of overall and disease-free survival of patients resected for cHCC-MFCCC versus those resected for HCC versus those resected for MFCCC

Time frame: From 3 months after surgery up to 60 months after surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.